CYP2B6

TerSera® to sponsor "NET Cancer Health Storylines" digital platform to support patients suffering from Carcinoid Syndrome Diarrhea

Retrieved on: 
Wednesday, December 7, 2022

"We are grateful for this support from TerSera to continue to enhance the NET Health Storylines platform to distribute meaningful educational content to NETs patients.

Key Points: 
  • "We are grateful for this support from TerSera to continue to enhance the NET Health Storylines platform to distribute meaningful educational content to NETs patients.
  • The resources available through this platform are important tools in supporting NET patients throughout their journey," said Keith Warner, Chief Executive Officer of the Carcinoid Cancer Foundation.
  • "Collaborating with CCF and the NET Cancer Health Storylines platform is a fantastic opportunity for us to support patients with Carcinoid Syndrome Diarrhea beyond our existing clinical nurse educator program.
  • The Carcinoid Cancer Foundation is the oldest nonprofit carcinoid and neuroendocrine cancer organization in the United States, founded in 1968.

Recordati Rare Diseases Announces Several Scientific Abstracts to Be Presented at the Upcoming Endo Society Annual Meeting

Retrieved on: 
Wednesday, June 8, 2022

Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June 11 14, 2022.

Key Points: 
  • Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June 11 14, 2022.
  • For more information visit www.isturisa.com
    About Recordati Rare Diseases Inc.
    Recordati Rare Diseases Inc. is a biopharmaceutical company committed to providing often-overlooked orphan therapies to the underserved rare disease communities of the United States.
  • Recordati Rare Diseases mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies.
  • We work side-by-side with rare disease communities to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases.

Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

Retrieved on: 
Wednesday, June 1, 2022

By utilizing precision medicine, medical professionals will be able to test patients for genetic, personal and familial insights to better inform each patients psychedelic assisted therapy experience.

Key Points: 
  • By utilizing precision medicine, medical professionals will be able to test patients for genetic, personal and familial insights to better inform each patients psychedelic assisted therapy experience.
  • The gene mutation CYP2B6 can influence the metabolism of ketamine for the 10-20% of people that carry a specific CYP2B6 gene variant.
  • Precision medicine will provide KetaDASH with the ability to tailor the treatment based on an individual or sub-groups variability in genes and lifestyle choice.
  • HaluGen's genetic-based psychedelic pre-screening platform helps evaluate an individual's overall sensitivity and risk profile when using hallucinogenic drugs.

Phase III LINC 3 Study Demonstrates That ISTURISA® (osilodrostat) Improves Physical Features Associated With Hypercortisolism in Patients With Cushing’s Disease

Retrieved on: 
Friday, May 13, 2022

Recordati Rare Diseases Inc. announced today that the Phase III LINC 3 study demonstrates ISTURISA (osilodrostat) improves physical features associated with hypercortisolism in patients with Cushings disease.

Key Points: 
  • Recordati Rare Diseases Inc. announced today that the Phase III LINC 3 study demonstrates ISTURISA (osilodrostat) improves physical features associated with hypercortisolism in patients with Cushings disease.
  • Patients with Cushings disease experience multiple physical manifestations of hypercortisolism that may reduce quality of life.
  • According to the abstract entitled Osilodrostat Therapy Improves Physical Features Associated with Hypercortisolism in Patients with Cushings Disease: Findings from the Phase III LINC 3 Study, 137 adult Cushings disease patients with mUFC >1.5 x the upper limit of normal were enrolled in the 48-week core phase to evaluate the safety and efficacy of ISTURISA in patients with Cushings disease.
  • Changes to physical features caused by Cushings disease can have a significant impact on patient health and well-being.

Recordati Rare Diseases Announces Multiple Scientific Abstracts to Be Highlighted at American Association of Clinical Endocrinology

Retrieved on: 
Tuesday, May 10, 2022

Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be featured onsite at the American Association of Clinical Endocrinology (AACE) annual meeting being held in San Diego, California from May 12 14, 2022.

Key Points: 
  • Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be featured onsite at the American Association of Clinical Endocrinology (AACE) annual meeting being held in San Diego, California from May 12 14, 2022.
  • Key Onsite abstracts presented by Alberto Pedroncelli MD, Head of Clinical Development & Medical Affairs, Global Endocrinology, Recordati AG.
  • For more information visit www.isturisa.com
    About Recordati Rare Diseases Inc.
    Recordati Rare Diseases Inc. is a biopharmaceutical company committed to providing often-overlooked orphan therapies to the underserved rare disease communities of the United States.
  • Recordati Rare Diseases mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies.

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

Retrieved on: 
Monday, March 9, 2020

Adverse drug reactions associated with Isturisa and occurring in greater than 20% of patients are adrenal insufficiency, fatigue, nausea, headache, and edema.

Key Points: 
  • Adverse drug reactions associated with Isturisa and occurring in greater than 20% of patients are adrenal insufficiency, fatigue, nausea, headache, and edema.
  • Correct hypokalemia and/or hypomagnesemia prior to ISTURISA initiation and monitor periodically during treatment with ISTURISA.
  • CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers.
  • A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA.